<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11864859</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.436</article-id><article-id pub-id-type="other">EPP0245</article-id><article-id pub-id-type="pii">S092493382400436X</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Evolution of Depression and Anxiety among Breast Cancer Patients: a prospective analysis using clinical, biological and genetic factors</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khoury</surname><given-names>R.</given-names></name><xref rid="aff0922" ref-type="aff">
<sup>1</sup></xref><xref rid="aff0923" ref-type="aff">
<sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hachem</surname><given-names>R.</given-names></name><xref rid="aff0922" ref-type="aff">
<sup>1</sup></xref><xref rid="aff0923" ref-type="aff">
<sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Salameh</surname><given-names>P.</given-names></name><xref rid="aff0924" ref-type="aff">
<sup>3</sup></xref><xref rid="aff0925" ref-type="aff">
<sup>4</sup></xref><xref rid="aff0926" ref-type="aff">
<sup>5</sup></xref><xref rid="aff0927" ref-type="aff">
<sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sacre</surname><given-names>H.</given-names></name><xref rid="aff0924" ref-type="aff">
<sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bedran</surname><given-names>M.</given-names></name><xref rid="aff0922" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rabbaa</surname><given-names>L.</given-names></name><xref rid="aff0922" ref-type="aff">
<sup>1</sup></xref><xref rid="aff0923" ref-type="aff">
<sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chahine</surname><given-names>G.</given-names></name><xref rid="aff0928" ref-type="aff">
<sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kattan</surname><given-names>J.</given-names></name><xref rid="aff0928" ref-type="aff">
<sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nasr</surname><given-names>F.</given-names></name><xref rid="aff0928" ref-type="aff">
<sup>7</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hajj</surname><given-names>A.</given-names></name><xref rid="aff0923" ref-type="aff">
<sup>2</sup></xref><xref rid="aff0924" ref-type="aff">
<sup>3</sup></xref><xref rid="aff0929" ref-type="aff">
<sup>8</sup></xref><xref rid="aff0930" ref-type="aff">
<sup>9</sup></xref><xref rid="cor0297" ref-type="corresp">
<sup>*</sup></xref></contrib></contrib-group><aff id="aff0922">
<sup>1</sup>Faculty of Pharmacy</aff><aff id="aff0923">
<sup>2</sup>Laboratoire de Pharmacologie, <institution>Pharmacie Clinique et Contr&#x000f4;le de Qualit&#x000e9; des M&#x000e9;dicaments, Saint Joseph University</institution>
</aff><aff id="aff0924">
<sup>3</sup><institution>INSPECT-LB (Institut National de Sant&#x000e9; Publique, d&#x02019;&#x000c9;pid&#x000e9;miologie Clinique et de Toxicologie-Liban)</institution>, <city>Beirut</city>
</aff><aff id="aff0925">
<sup>4</sup><institution>School of Medicine, Lebanese American University</institution>, <city>Byblos</city>, <country>Lebanon</country>
</aff><aff id="aff0926">
<sup>5</sup>Department of Primary Care and Population Health, <institution>University of Nicosia Medical School</institution>, <city>Nicosia</city>, <country>Cyprus</country>
</aff><aff id="aff0927">
<sup>6</sup>Faculty of Pharmacy, <institution>Lebanese University</institution>, <city>Hadat</city>
</aff><aff id="aff0928">
<sup>7</sup>Department of Hemato-Oncology, H&#x000f4;tel-Dieu de France Hospital, Faculty of Medicine, <institution>Saint Joseph University of Beirut</institution>, <city>Beirut</city>, <country>Lebanon</country>
</aff><aff id="aff0929">
<sup>8</sup>Faculty of Pharmacy, <institution>Universit&#x000e9; Laval</institution>
</aff><aff id="aff0930">
<sup>9</sup>Oncology Division, <institution>CHU de Qu&#x000e9;bec- Universit&#x000e9; Laval Research Center</institution>, <city>Quebec</city>, <country>
Canada</country>
</aff><author-notes><corresp id="cor0297">
<label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="411">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S202</fpage><lpage>S203</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S092493382400436Xa.pdf"/><abstract><sec id="sec1783"><title>Introduction</title><p>Numerous studies have explored the symptoms and course of depression and anxiety in breast cancer patients and identified various clinical, sociodemographic, and genetic factors associated with their evolution. Nevertheless, these studies have been limited in duration and have focused on specific time points during chemotherapy or post-treatment follow-up. Furthermore, these studies included patients receiving different treatment regimens and used different tools to assess symptoms.</p></sec><sec id="sec1784"><title>Objectives</title><p>
To assess the prospective evolution of depression in breast cancer patients over eight consecutive chemotherapy cycles, taking into account sociodemographic, clinical, biological, and genetic factors.</p></sec><sec id="sec1785"><title>Methods</title><p>A prospective longitudinal study was conducted on 69 breast cancer patients treated with intravenous chemotherapy at the oncology outpatient unit of the H&#x000f4;tel-Dieu de France hospital (2017-2019; Ethics: CEHDF1016). The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression in patients. Genotyping was performed for several genes (<italic toggle="yes">ABCB1, COMT</italic>, <italic toggle="yes">DRD2, OPRM1</italic>, <italic toggle="yes">CLOCK, CRY2</italic>, <italic toggle="yes">PER2</italic>) using the Lightcycler<sup>&#x000ae;</sup> 2.0 (Roche).</p></sec><sec id="sec1786"><title>Results</title><p>Univariate repeated measures analysis showed differences in the evolution of depression and anxiety over time. For depression, a polynomial linear contrast for HADS-D scores was noted from cycle 1 to cycle 8, with a significant increase in depression at cycles 7 and 8 compared with cycle 1 (p-value
<sub>cycle7</sub>=0.004 and p-value<sub>cycle8</sub>=0.009; Figures 1 &#x00026; 2). Repeated measures analysis for anxiety showed a decrease in anxiety scores between cycles 1 and 6 of chemotherapy, followed by an increase starting cycle 6 (a polynomial trend for contrasts) (p-value
<sub>cycle6 versus 1</sub>=0.038; Figures 1 &#x00026; 2). Multivariable analysis showed that higher anxiety and depression scores at baseline were both associated with higher depression and anxiety scores over time. Other clinical and genetic factors, including polymorphisms in the <italic toggle="yes">OPRM1</italic>, 
<italic toggle="yes">PER2,
</italic> and <italic toggle="yes">COMT</italic> genes, were also significantly associated with higher depression and anxiety scores.</p><p>
<bold>Image:</bold></p><p>
<fig position="float" id="fig0043"><graphic xlink:href="S092493382400436X-FIG0043" position="anchor"/></fig>
</p><p>
<bold>Image 2:</bold>
</p><p>
<fig position="float" id="fig0044"><graphic xlink:href="S092493382400436X-FIG0044" position="anchor"/></fig>
</p></sec><sec id="sec1787"><title>Conclusions</title><p>Our findings highlight the importance of understanding the trajectories of depression and anxiety over time in women with breast cancer and identifying the triggering factors. Such personalized approaches would improve patient quality of life.</p></sec><sec id="sec1788"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>